CVS Health Corp NYSE:CVS Price, Chart, News & Insight

CVS Health Plans Tax-Free Split Into Two Public Companies by 2028

CVS Health (NYSE: CVS) plans to separate into two independent publicly traded companies, splitting its healthcare solutions operations from its retail pharmacy business. The transaction is expected to be completed in the first half of 2028.

One company, which will retain the CVS Health name, will include Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The second, CVS Pharmacy, will include roughly 9,000 retail pharmacies, mail pharmacy, MinuteClinic and the Health100 technology business.

CVS said the separation should give each business a more focused strategy, independent capital structure and greater flexibility to invest and allocate capital. Both companies are expected to maintain investment-grade ratings and generate strong free cash flow.

The transaction is intended to be tax-free to CVS Health and its shareholders, who are expected to own shares in both companies following the separation.

💬

WS Investor 11-04-26

CVS Health Plunges 12.5% Despite Higher Guidance as Medical Cost Concerns Persist

CVS Health (NYSE: CVS) shares fell about 12.5% after the company reported stronger third-quarter earnings and raised its full-year outlook, but maintained a cautious view on elevated medical cost trends and potential macroeconomic headwinds.

Third-quarter revenue increased 5.4% year over year to $108.4 billion. Adjusted EPS rose to $2.09 from $1.60, while adjusted operating income increased 21.2% across the company’s operating segments.

The Health Care Benefits segment showed meaningful improvement. Adjusted operating income climbed to $912 million from $314 million, while the medical benefit ratio improved to 91.3% from 92.8%. CVS attributed the improvement mainly to stronger underlying performance in its government business.

Health Services revenue rose 9.5% to $54.0 billion, while adjusted operating income increased 2.7% to $2.11 billion. Pharmacy & Consumer Wellness revenue fell 2.0% to $35.5 billion, but adjusted operating income increased 10.6% to $1.64 billion, supported by core pharmacy strength and contributions from Rite Aid asset acquisitions.

CVS raised its 2026 adjusted EPS guidance to at least $8.20 from a previous range of $7.90-$8.10. GAAP EPS guidance was increased to at least $6.98, while operating cash flow guidance rose sharply to at least $15.5 billion from at least $11.5 billion. :chatgpt-content-reference{index="6"}

However, management also said it remains cautious for the rest of the year because of continued elevated cost trends and possible macroeconomic pressures.

The sharp 12.5% decline suggests investors are looking beyond the headline guidance increase and focusing on the durability of the margin recovery in CVS’s insurance business. The medical benefit ratio improved materially, but it remains elevated, while the company’s explicit warning on cost trends may be raising concerns that recent earnings improvement could prove harder to sustain than the stronger quarterly numbers imply.

💬

WS Investor 11-04-26

CVS Health’s Aetna Expands Bundled Cancer Prior Authorizations

CVS Health’s Aetna is expanding bundled prior authorizations across all cancer types for eligible Medicaid members, with plans to extend the model across all lines of business in 2027.

The approach allows providers to submit a single prior authorization covering multiple related cancer services, including chemotherapy, immunotherapy, radiation oncology and associated imaging such as MRI and CT scans. Aetna said providers had previously submitted an average of four separate prior authorization requests for each member undergoing cancer treatment.

Aetna said nearly 25% of eligible members are already receiving bundled prior authorizations following the initial rollout. The company expects the expanded process to reduce administrative work and speed patient access to approved treatment services.

The insurer cited provider survey data showing that 74% of respondents viewed administrative burden as their biggest clinical challenge, while 31% identified prior authorization management as the single largest contributor.

Aetna plans to expand eligibility to Medicare and commercial members in the first half of 2027, broadening the program beyond Medicaid.

💬

The Investor 09-17-26

CVS Health (CVS) Stock Falls 6% Despite Strong Q2 Earnings and Higher Guidance

CVS Health (NYSE: CVS) shares fell around 6% on Wednesday despite reporting strong second-quarter results, raising its full-year earnings guidance, and improving profitability across its healthcare businesses. Investors appeared to focus on management's cautious comments about elevated healthcare costs and macroeconomic uncertainty, overshadowing an otherwise solid quarter.

Strong Earnings and Higher Outlook

CVS reported second-quarter revenue of $106.1 billion, up 7.3% year over year, while adjusted EPS climbed to $2.58 from $1.81 a year earlier. The company also generated $10.6 billion in year-to-date operating cash flow.

Management raised its full-year outlook, now expecting:

* GAAP EPS of $6.84 to $7.04
* Adjusted EPS of $7.90 to $8.10
* Operating cash flow of at least $11.5 billion

The higher guidance reflects continued improvement in the Health Care Benefits and Pharmacy & Consumer Wellness businesses.

Insurance Business Continues to Recover

The company's Health Care Benefits segment remained the biggest earnings driver. Adjusted operating income jumped 85.5% year over year, while the medical benefit ratio improved to 87.4% from 89.9%, reflecting better claims experience and continued execution of CVS's margin recovery strategy.

CVS also continued expanding its GLP-1 weight-loss offerings and AI-powered healthcare tools to improve patient engagement and claims processing.

Why the Stock Fell

Despite the strong results, investors appeared concerned that management maintained a cautious outlook for the remainder of 2026, citing continued elevated healthcare cost trends and potential macroeconomic headwinds.

After several quarters of improving performance, expectations heading into the earnings release were high, and the stronger guidance may not have been enough to offset concerns that healthcare costs could remain a headwind.

What Investors Are Watching

Investors will continue monitoring medical cost trends, the recovery of insurance margins, pharmacy reimbursement conditions, and the rollout of CVS's GLP-1 and AI initiatives. While Wednesday's share decline reflected cautious sentiment, the quarter demonstrated continued operational improvement and stronger earnings momentum across the company's integrated healthcare platform.

💬

The Investor 08-05-26

CVS Health Jumps 6% After Raising Full-Year Guidance on Insurance Margin Recovery

May 6, 2026 · Earnings Report

CVS Health surged 6% today after reporting first quarter 2026 results that beat expectations and prompted the company to raise its full-year earnings and cash flow guidance, with the Health Care Benefits segment delivering a dramatic improvement that reassured investors who had been watching the insurer's margin recovery closely.

Total revenues for the quarter came in at $100.4 billion, up 6.2% year-over-year, with growth across all three operating segments. GAAP diluted EPS rose to $2.30 from $1.41 in the prior year, while adjusted EPS increased to $2.57 from $2.25, beating expectations. Operating income jumped 38.7% to $4.68 billion, and adjusted operating income grew 12.5% to $5.15 billion. Cash flow from operations was $4.2 billion for the quarter.

The standout was the Health Care Benefits segment, which houses the Aetna insurance business. Adjusted operating income for the segment surged 52.6% to $3.04 billion, as the medical benefit ratio improved sharply to 84.6% from 87.3% a year ago, reflecting better underlying performance in the government business and the absence of a $448 million premium deficiency reserve recorded in the prior year. The improvement validated the company's much-discussed margin recovery plan, which had been a central concern for investors after a difficult 2025. Medical membership stood at 26.0 million as of March 31, down from 27.1 million a year ago, reflecting CVS's exit from the individual exchange business in 2026.

The Health Services segment, which includes pharmacy benefit management, posted revenues up 11.0% to $48.2 billion, though adjusted operating income dipped 7.1% to $1.49 billion due to continued pharmacy client price improvements. The Pharmacy and Consumer Wellness segment, which includes retail pharmacies, saw revenues hold roughly flat at $32.0 billion, with prescription volumes up 3.6% partly aided by the Rite Aid asset acquisitions completed in mid-2025, though adjusted operating income declined 8.8% due to reimbursement pressure and weather-related disruptions.

On the strategic front, CVS announced the launch of Health100, a health technology subsidiary that will use Google Cloud's AI technologies to deliver an integrated health care engagement platform for consumers. The company also unveiled plans for smaller pharmacy-focused retail locations and highlighted meaningful progress on prior authorization reform through Aetna, including approving more than 95% of eligible prior authorizations within 24 hours and eliminating over one million provider calls through automation.

For the full year 2026, CVS raised its GAAP diluted EPS guidance to a range of $6.24 to $6.44, up from the prior range of $5.94 to $6.14. Adjusted EPS guidance was lifted to $7.30 to $7.50 from $7.00 to $7.20, and cash flow from operations guidance was raised to at least $9.5 billion from at least $9.0 billion. The company noted it was maintaining a cautious view for the remainder of the year given continued elevated cost trends and potential macro headwinds.

💬

Global Finance News 05-06-26

CVS Health® (NYSE: CVS) will hold a conference call on Wednesday, May 6th, 2026, at 8:00 a.m. ET on first quarter 2026 financial results.

💬

Global Finance News 04-07-26

CVS Health announced that its subsidiary Omnicare has entered into an asset purchase agreement with GenieRx Holdings as part of an ongoing court-supervised sale process.

GenieRx will act as the “stalking horse bidder,” setting a baseline value for Omnicare’s assets while allowing competing bids. The deadline for alternative offers is April 30, with a potential auction scheduled for May 5, 2026.

Omnicare said it will continue operating normally during the process, maintaining pharmacy services for long-term care facilities, including skilled nursing and assisted living communities.

The company emphasized that the agreement reflects continued interest in its business and supports efforts to maximize value while ensuring uninterrupted care for patients.

💬

Global Finance News 04-03-26

CVS Health announced the opening of its first pharmacy-only CVS Pharmacy location in Chicago, marking the start of a broader rollout of smaller, dedicated pharmacy formats.

The company plans to open nearly 20 such locations in 2026, designed to improve access to medications, vaccinations, and pharmacist consultations, particularly in underserved communities.

These compact, apothecary-style stores focus on core pharmacy services with a limited retail offering, aiming to enhance patient interaction and provide more personalized care.

The initiative reflects CVS’s strategy to adapt its retail footprint and meet evolving healthcare needs, emphasizing in-person pharmacist engagement alongside digital services.

💬

WS Investor 03-30-26

CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of $0.665 cents per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026.

💬

Global Finance News 03-19-26

CVS Health and Google Cloud partner to develop AI-driven healthcare engagement platform

CVS Health and Google Cloud have announced a strategic partnership to develop a new AI-powered healthcare consumer engagement platform through CVS Health’s newly launched technology subsidiary, Health100.

The platform will use Google Cloud’s AI technologies, including Gemini models, Cloud Healthcare API and BigQuery, to create an integrated system that connects patients with pharmacies, healthcare providers, insurers and digital health services. The AI-native platform aims to deliver real-time, personalized health support, improve access to care and help consumers manage healthcare costs.

CVS Health said the Health100 platform is designed to provide an always-on digital health partner that can guide patients through care decisions and connect them with services such as pharmacist-led care management. The platform is expected to launch in 2026 and will allow other healthcare innovators to build applications within its ecosystem.

💬

The Investor 03-07-26

NYSE:CVSFollow

NYSE:CVS